➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKinsey
McKesson
Merck
Express Scripts

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

SODIUM NITROPRUSSIDE Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Sodium Nitroprusside, and when can generic versions of Sodium Nitroprusside launch?

Sodium Nitroprusside is a drug marketed by Abraxis Pharm, Akorn, Amneal, Amphastar Pharms Inc, Aurobindo Pharma Ltd, Baxter Hlthcare, Cipla, Dr Reddys Labs Ltd, Hainan Poly Pharm, Hong Kong, Medicure, Micro Labs, Mylan Labs Ltd, Nexus Pharms, Sagent Pharms Inc, Somerset Theraps Llc, Sun Pharm, Teva Parenteral, Virtus Pharm, and Xiromed. and is included in twenty NDAs.

The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Nitroprusside

A generic version of SODIUM NITROPRUSSIDE was approved as sodium nitroprusside by SAGENT PHARMS INC on December 8th, 2016.

  Get Started Free

Drug patent expirations by year for SODIUM NITROPRUSSIDE
Drug Prices for SODIUM NITROPRUSSIDE

See drug prices for SODIUM NITROPRUSSIDE

Recent Clinical Trials for SODIUM NITROPRUSSIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityEarly Phase 1
Dr. Graeme SmithEarly Phase 1
Shaanxi Provincial People's HospitalPhase 1/Phase 2

See all SODIUM NITROPRUSSIDE clinical trials

Pharmacology for SODIUM NITROPRUSSIDE
Drug ClassVasodilator
Physiological EffectVasodilation

US Patents and Regulatory Information for SODIUM NITROPRUSSIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 070031-001 Jan 17, 1985 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Teva Parenteral SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 073465-001 Mar 30, 1992 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Cipla SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 210855-001 Jul 16, 2018 AP RX No No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKinsey
Dow
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.